Framingham Alzheimer's pharma firm reports promising drug trial results
Image | Courtesy of Google Maps
Alzheon headquarters in Framingham
Framingham-based Alzheon, a clinical stage biopharmaceutical research and development firm, on Wednesday reported statistically significant results in brain preservation from a phase two trial of an early Alzheimer's disease drug.
The drug, Oral ALZ-801, is intended to significantly slow or stop Alzheimer’s disease progression and potentially prevent or delay the onset of clinical symptoms, according to Alzheon’s website.
Following a 24-month phase two trial of the drug, the company reports drug-takers improved performance on cognitive tests and maintained volume in the hippocampus part of the brain to a statistically significant degree, according to a Wednesday press release from the company.
“We are pleased with the growing body of evidence that supports ALZ-801’s potential as the first oral disease modifying therapy for Alzheimer’s disease,” Dr. Martin Tolar, founder, president, and CEO of Alzheon, said in the press release.
The drug will enter the third phase of the trial, with results expected in quarter three 2024. The drug has so far shown the most favorable results in older adults with two gene copies of the leading genetic marker for Alzheimer's.
WBJ Web Partners
Most Recent
Most Recent
0 Comments